iCP-NI / Cellivery - LARVOL DELTA

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects (clinicaltrials.gov) - P1 | N=24 | Terminated | Sponsor: Cellivery Therapeutics, Inc. | N=64 ➔ 24 | Suspended ➔ Terminated; Closed by Sponsor for business reasons

Enrollment change • Trial termination

Intracellular delivery of nuclear localization sequence peptide mitigates COVID-19 by inhibiting nuclear transport of inflammation associated transcription factors. (PubMed, Mol Ther) - "Similarly, in hamsters infected with SARS-CoV-2, iCP-NI effectively protected the lung from inflammatory damage by reducing TNF-α, IL-6, and IL-17 levels. These promising results highlight iCP-NI's potential as a therapeutic approach for COVID-19-related lung complications and other inflammatory lung diseases."

Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL17A • IL6 • TNFA

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects (clinicaltrials.gov) - P1 | N=64 | Suspended | Sponsor: Cellivery Therapeutics, Inc. | Recruiting ➔ Suspended

Trial suspension

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Cellivery Therapeutics, Inc.

New P1 trial

Intracellularly Delivered Nuclear Localization Sequence Attenuates The Severity Of COVID-19 By Inhibits Interaction Of Inflammatory Transcription Factors And Importins (IMMUNOLOGY 2022) - "Likewise, the levels of inflammatory cytokines such as TNF-α and IL-17A in the lungs are significantly decreased and thereby, the lung structures are protected from inflammation-mediated damages. As a result, the iCP-NI could be developed as a novel medicine to cure various inflammatory diseases including COVID-19."

Acute Respiratory Distress Syndrome • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL17A • STAT1 • TNFA

Intracellular Delivery Of Nuclear Localization Signal Relieves Inflammatory Pulmonal Disease Through Regulating Immune System By Patient-Friendly Inhalant Formulation (IMMUNOLOGY 2022) - "Also, iCP-NI inhibited the recruitment of neutrophils (99.8%) and macrophages (99.6%) in BALF, and thereby induced the restoration of damaged lung tissue. In conclusion, iCP-NI has a significant therapeutic effect on COPD through immune system control and potential as a patient-friendly anti-inflammatory drug."

Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • ELANE • IL6 • TNFA

Cellivery "Intrinsic Immune Control Inflammation Treatment, Formulation Completed by Indication" [Google translation] (Hankyung) - "Shelly discard...announced that it has signed a Euro-pin and 23 days of inhaled formulation formulation development and manufacturing contract with a global formulation foster professional development and production organizations (CDMO) Luxembourg. This is to develop...'iCP-NI' as a treatment for refractory autoimmune respiratory diseases."

Licensing / partnership • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Cellivery announces the efficacy of anti-inflammatory drug iCP-NI on the treatment of autoimmune disease Soriasis at JPMorgan conference (Google translation) (Pax Economic TV) - "Cellibury (CEO Daewoong Cho) presented the latest research results of `iCP-NI, an autoimmune disease Soriasis (psoriasis) treatment' at the JPMorgan Healthcare Conference (JPMHC) in 2021 to global pharmaceutical companies on the 14th...'In the skin tissues of the Soriasys disease model, iCP-NI reduced the penetration of inflammation-inducing immune cells (T cells) into skin tissues by 80%'...'By reducing alpha (TNF-α) and interleukin-22 (IL-22) by 66% and 90%, respectively, it showed strong anti-inflammation and anti-psoriasis treatment effects.'"

Preclinical • Psoriasis